Friday 17 April 2026

Pharma & Biotech Start-up & Scale-up News

Featured

CNX Therapeutics
A pharmaceutical company, based in USA, developing small molecule-based therapeutics for neurological and hepatological with a focus on addressing unmet medical need.
Biotechnology
Biocytogen inks antibody deal with BeOne, expanding strategic ties
10 July 2025
article
IDEAYA exercises option for license on Biocytogen’s IDE034
11 November 2024

Latest Ones To Watch News

Biotechnology
MeiraGTx reacquires bota-vec rights and prices public offering
16 April 2026
Biotechnology
Alethio Therapeutics unveils ATX-011, a breakthrough for treating essential thrombocythemia
16 April 2026
Biotechnology
Terremoto investors see ‘full potential of selective AKT1 inhibition’
16 April 2026
More ones to watch news >
Reset all filters
Refine search
Ewopharma
Ewopharma
Travere Therapeutics
Travere Therapeutics
OriCell Therapeutics
Annovis Bio
Cue Biopharma
Soleno Therapeutics
MoonLake Immunotherapeutics
Excellergy
Terns Pharmaceuticals
Karyopharm Therapeutics
Rhythm Pharmaceuticals
Ovid Therapeutics
Alto Neuroscience
Purple Biotech
BeOne Medicines
Medicus Pharma
Antengene
Priovant Therapeutics
Abcuro
Protara Therapeutics


Today's issue

Ryght AI introduces world’s first, free, AI-powered clinical trial site search engine
Pharmaceutical
Ryght AI introduces world’s first, free, AI-powered clinical trial site search engine
17 April 2026
Biotechnology
MeiraGTx reacquires bota-vec rights and prices public offering
16 April 2026
Biotechnology
Alethio Therapeutics unveils ATX-011, a breakthrough for treating essential thrombocythemia
16 April 2026
Pharmaceutical
ICER white paper on accelerated approval pathway for Rx drugs
16 April 2026
Pharmaceutical
Daiichi Sankyo transfers healthcare unit to Suntory
16 April 2026
Biosimilars
Mochida inks agreement for a biosimilar of follitropin alfa
16 April 2026
Biotechnology
Terremoto investors see ‘full potential of selective AKT1 inhibition’
16 April 2026


Company Spotlight

A pharmaceutical company, based in USA, developing small molecule-based therapeutics for neurological and hepatological with a focus on addressing unmet medical need.




Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze